

Part

12 膠原病

第1章 関節リウマチ

◎参考文献

1. Hochberg MC, et al. Clinical features of rheumatoid arthritis. In : Rheumatology. 7th ed. Philadelphia : Elsevier, 2019 : 760-7.
2. Firestein GS, et al. Clinical features of rheumatoid arthritis. In : Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia : Elsevier, 2016.
3. Hochberg MC, et al. The wrist and hand. Anatomy of the Ankle and Foot. In : Rheumatology. 7th ed. Philadelphia : Elsevier, 2019 : 673-704.
4. Firestein GS, et al. Evaluation and Differential Diagnosis of Polyarthritis. In : Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia : Elsevier, 2016.
5. Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010 ; 62 : 2569-81. PMID : 20872595
6. Sparks JA, et al. Associations of Smoking and Age With Inflammatory Joint Signs Among Unaffected First-Degree Relatives of Rheumatoid Arthritis Patients : Results From Studies of the Etiology of Rheumatoid Arthritis. *Arthritis Rheumatol* 2016 ; 68 : 1828-38. PMID : 26866831
7. Vesperini V, et al. Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis : results from a French multicenter cohort. *Arthritis Care Res (Hoboken)* 2013 ; 65 : 1899-906. PMID : 23836776
8. van Steenberg HW, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. *Ann Rheum Dis* 2017 ; 76 : 491-6. PMID : 27991858
9. 日本リウマチ学会. ACR/EULAR 新分類基準の検証結果について.<<https://www.ryumachi-jp.com/information/medical/news120115/>>
10. Conforti A, et al. Musculoskeletal adverse drug reactions : a review of literature and data from ADR spontaneous reporting databases. *Curr Drug Saf* 2007 ; 2 : 47-63. PMID : 18690950
11. Mikuls TR, et al. *Porphyromonas gingivalis* and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. *Arthritis Rheum* 2012 ; 64 : 3522-30. PMID : 22736291
12. Patel SJ, et al. Ocular manifestations of autoimmune disease. *Am Fam Physician* 2002 ; 66 : 991-8. PMID : 12358224
13. Shaw M, et al. Rheumatoid arthritis-associated lung disease. *Eur Respir Rev* 2015 ; 24 : 1-16. PMID : 25726549
14. Hochberg MC, et al. Autoantibodies in rheumatoid arthritis. In : Rheumatology. 7th ed. Philadelphia : Elsevier, 2019 : 803-10.
15. Ingegnoli F, et al. Rheumatoid factors : clinical applications. *Dis Markers* 2013 ; 35 :

- 727-34. PMID : 24324289
16. Aggarwal R, et al. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. *Arthritis Rheum* 2009 ; 61 : 1472-83. PMID : 19877103
17. Hochberg MC, et al. Imaging of rheumatoid arthritis. In : *Rheumatology*. 7th ed. Philadelphia : Elsevier, 2019 : 777-86.
18. Brower AC, et al. *Arthritis in Black & White*. 3th ed. Philadelphia : Elsevier, 2012.
19. Firestein GS, et al. Imaging in Rheumatic Disease. In : *Kelley and Firestein's Textbook of Rheumatology*. 10th ed. Philadelphia : Elsevier, 2016.
20. van Gaalen FA, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis : a prospective cohort study. *Arthritis Rheum* 2004 ; 50 : 709-15. PMID : 15022309
21. Anderson J, et al. Rheumatoid arthritis disease activity measures : American College of Rheumatology recommendations for use in clinical practice. *Arthritis Care Res (Hoboken)* 2012 ; 64 : 640-7. PMID : 22473918
22. 日本リウマチ学会. 関節リウマチ診療ガイドライン 2014. 大阪 : メディカルレビュー, 2014. **ガイドライン**
23. Singh JA, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)* 2016 ; 68 : 1-25. PMID : 26545825 **ガイドライン**
24. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. *Ann Rheum Dis* 2017 ; 76 : 960-77. PMID : 28264816
25. 日本リウマチ学会. 関節リウマチ治療におけるメトトレキサート診療ガイドライン 2016年改訂版. 東京 : 羊土社, 2016 **ガイドライン**
26. 日本リウマチ学会. 関節リウマチ診療ガイドライン JCR2014に基づく一般医向け診療ガイドライン.<https://www.ryumachi-jp.com/info/RA_guideline.pdf> **ガイドライン**
27. 難病情報センター. 悪性関節リウマチ (指定難病 46).<<https://www.nanbyou.or.jp/entry/205>>
28. Ball GV, et al. *Oxford Textbook of Vasculitis*. 3rd ed. Oxford : Oxford University Press, 2014 : 443-65.
29. Park JH, et al. Prognosis of fibrotic interstitial pneumonia : idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care Med* 2007 ; 175 : 705-11. PMID : 17218621

● リンクページ

- 問診表 (日本リウマチ学会. 「ACR/EULAR 新分類基準の検証結果について」より)
<https://www.ryumachi-jp.com/info/120115_table2.pdf>
- DAS-score website. (ONLINE DAS CALCULATOR)
<<https://www.das-score.nl/en/>>
- 関節リウマチ診療ガイドライン 2014 治療アルゴリズム
<http://minds4jqchc.or.jp/minds/Rheumatoid_arthritis/med0064/illu02_01.html>
- 悪性関節リウマチ 診断基準 [難病情報センター. 悪性関節リウマチ (指定難病 46) より]
<<https://www.nanbyou.or.jp/entry/205>>

第2章 リウマチ性多発筋痛症 (PMR) /RS3PE

◎参照文献

1. Kimura M, et al. Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. *J Rheumatol* 2012 ; 39 : 148-53. PMID : 22174210
2. Dejaco C, et al. 2015 Recommendations for the management of polymyalgia rheumatica : a European League Against Rheumatism/American College of Rheumatology collaborative initiative. *Ann Rheum Dis* 2015 ; 74 : 1799-807. PMID : 26359488
3. Dasgupta B, et al. 2012 provisional classification criteria for polymyalgia rheumatica : a European League Against Rheumatism/American College of Rheumatology collaborative initiative. *Ann Rheum Dis* 2012 ; 71 : 484-92. PMID : 22388996
4. Dasgupta B, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. *Rheumatology (Oxford)* 2010 ; 49 : 186-90. PMID : 19910443 **ガイドライン**
5. Bird HA, et al. An evaluation of criteria for polymyalgia rheumatica. *Ann Rheum Dis* 1979 ; 38 : 434-9. PMID : 518143
6. Matsui K, et al. Assessment of 2012 EULAR/ACR new classification criteria for polymyalgia rheumatica in Japanese patients diagnosed using Bird's criteria. *Int J Rheum Dis* 2018 ; 21 : 497-501. PMID : 28264228
7. Salvarani C, et al. Polymyalgia rheumatica and giant-cell arteritis. *N Engl J Med* 2002 ; 347 : 261-71. PMID : 12140303
8. Salvarani C, et al. Polymyalgia rheumatica and giant-cell arteritis. *Lancet* 2008 ; 372 : 234-45. PMID : 18640460
9. Yao Q, et al. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? *Semin Arthritis Rheum* 2010 ; 40 : 89-94. PMID : 19217650
10. Muller S, et al. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. *Ann Rheum Dis* 2014 ; 73 : 1769-73. PMID : 23842460
11. 陶山恭博. Q18 リウマチ性多発筋痛症と巨細胞性動脈炎の診かたは? In: 金城光代編. *jmedmook44 あなたも名医! 外来で診るリウマチ・膠原病 Q&A*. 東京: 日本医事新報社, 2016 : 111-9. **推奨文献**

第3章 結晶誘発性関節炎

◎参照文献

1. Firestein GS, et al. Calcium Crystal Disease Calcium Pyrophosphate Dihydrate and Basic Calcium Phosphate. In: Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia : Elsevier, 2016 : 1645-65.
2. Neogi T, et al. 2015 Gout Classification Criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheumatol* 2015 ; 67 : 2557-68. PMID : 26352873
3. 日本痛風・核酸代謝学会ガイドライン改訂委員会編. 2019年改訂 高尿酸血症・痛風の治療ガイドライン 第3版. 東京: 診断と治療社, 2018. <https://minds.jcqh.or.jp/docs/gl_pdf/G0001086/4/Clinical_Practice_Guidelines_of_Hyperuricemia_and_Gout>

pdf>

ガイドライン

4. Rainer TH, et al. Oral Prednisolone in the Treatment of Acute Gout : A Pragmatic, Multicenter, Double-Blind, Randomized Trial. *Ann Intern Med* 2016 ; 164 : 464-71.
PMID : 26903390
5. Janssens HJEM, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis : a double-blind, randomised equivalence trial. *Lancet* 2008 ; 371 : 1854-60.
PMID : 18514729
6. Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis* 2017 ; 76 : 29-42.
PMID : 27457514
7. Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2 : therapy and antiinflammatory prophylaxis of acute gouty arthritis. *Arthritis Care Res (Hoboken)* 2012 ; 64 : 1447-61.
PMID : 23024029 **ガイドライン**
8. Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1 : systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken)* 2012 ; 64 : 1431-46.
PMID : 23024028 **ガイドライン**

第4章 全身性エリテマトーデス (SLE)

◎参照文献

1. Fanouriakis A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019 ; 78 : 736-45.
PMID : 30926722
2. Dörner T, et al. Novel paradigms in systemic lupus erythematosus. *Lancet* 2019 ; 393 : 2344-58.
PMID : 31180031
3. 日本リウマチ学会編. 全身性エリテマトーデス診療ガイドライン 2019. 東京 : 南山堂, 2019. **ガイドライン**
4. Petri M, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012 ; 64 : 2677-86.
PMID : 22553077
5. Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis* 2019 ; 78 : 1151-9.
PMID : 31383717
6. Franklyn K, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). *Ann Rheum Dis* 2016 ; 75 : 1615-21.
PMID : 26458737
7. Gladman DD, et al. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol* 2002 ; 29 : 288-91.
PMID : 11838846
8. Petri M, et al. Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med* 2005 ; 353 : 2550-8.
PMID : 16354891
9. Petri M, et al. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. *Arthritis Rheumatol* 2018 ; 70 : 1790-5.
PMID : 29806142
10. Bertsias GK, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA)

- recommendations for the management of adult and paediatric lupus nephritis. *Ann Rheum Dis* 2012 ; 71 : 1771-82. PMID : 22851469
11. 「関節リウマチ (RA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針の作成」研究班編. 全身性エリテマトーデス (SLE), 関節リウマチ (RA), 若年性特発性関節炎 (JIA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針. 2018 <<https://ra-ibd-sle-pregnancy.org/>>
 12. Gladman DD, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. *J Rheumatol* 2003 ; 30 : 1955-9. PMID : 12966597
 13. Thamer M, et al. Prednisone, lupus activity, and permanent organ damage. *J Rheumatol* 2009 ; 36 : 560-4. PMID : 19208608
 14. Urowitz MB, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. *Arthritis Care Res (Hoboken)* 2012 ; 64 : 132-7. PMID : 21954226
 15. Hahn BH, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res (Hoboken)* 2012 ; 64 : 797-808. PMID : 22556106 **ガイドライン**
 16. 日本リウマチ学会. 皮膚エリテマトーデスおよび全身性エリテマトーデスに対するヒドロキシクロロキン使用のための簡易ガイドライン (2015. 10. 20 版). <https://www.ryumachi-jp.com/info/guideline_hcq.pdf> **ガイドライン**

● リンクページ

- SLEDAI-2K
<<https://www.jrheum.org/content/jrheum/29/2/288.full.pdf>>
- SELENA-SLEDAI
<https://www.nejm.org/doi/suppl/10.1056/NEJMoa051135/suppl_file/nejm_petri_2550sa1.pdf>

第5章 皮膚筋炎/多発筋炎

● 参考文献

1. Nagaraju K, et al. Inflammatory Disease of Muscle and Other Myopathy. In : Firestein GS, et al. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia : Elsevier, 2016.
2. Hochberg MC, et al. Rheumatology. 7th ed. Philadelphia : Elsevier, 2019 : 1329-37.
3. Sontheimer RD. Dermatomyositis : an overview of recent progress with emphasis on dermatologic aspects. *Dermatol Clin* 2002 ; 20 : 387-408. PMID : 12170874
4. Tanimoto K, et al. Classification criteria for polymyositis and dermatomyositis. *J Rheumatol* 1995 ; 22 : 668-74. PMID : 7791161
5. Klein M, et al. Arthritis in idiopathic inflammatory myopathy : clinical features and autoantibody associations. *J Rheumatol* 2014 ; 41 : 1133-9. PMID : 24786927
6. Gono T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. *Rheumatology (Oxford)* 2010 ; 49 : 1713-9. PMID : 20498012
7. Tanizawa K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. *Respir Med* 2011 ; 105 : 1380-7. PMID : 21632230

8. Watanabe K, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. *Respir Med* 2011 ; 105 : 1238-47. PMID : 21514811
9. Ma X, et al. Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. *Clin Rheumatol* 2016 ; 35 : 489-93. PMID : 26149923
10. Hill CL, et al. Frequency of specific cancer types in dermatomyositis and polymyositis : a population-based study. *Lancet* 2001 ; 357 : 96-100. PMID : 11197446
11. Chinoy H, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. *Ann Rheum Dis* 2007 ; 66 : 1345-9. PMID : 17392346
12. Bohan A, et al. Polymyositis and dermatomyositis (first of two parts). *N Engl J Med* 1975 ; 292 : 344-7. PMID : 1090839
13. Lundberg IE, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Ann Rheum Dis* 2017 ; 76 : 1955-64. PMID : 29079590
14. 難病情報センター. 皮膚筋炎/多発性筋炎 (指定難病 50). <<https://www.nanbyou.or.jp/entry/4080>>
15. Schreiber SL, et al. The mechanism of action of cyclosporin A and FK506. *Immunol Today* 1992 ; 13 : 136-42. PMID : 1374612
16. Kurita T, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. *Rheumatology (Oxford)* 2015 ; 54 : 39-44. PMID : 24764266
17. Nagasaka K, et al. Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. *Mod Rheumatol* 2003 ; 13 : 231-8. PMID : 24387210
18. Oddis CV, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. *Lancet* 1999 ; 353 : 1762-3. PMID : 10347992
19. Kameda H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. *J Rheumatol* 2005 ; 32 : 1719-26. PMID : 16142867
20. Takada K, et al. Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis : a retrospective study. *Mod Rheumatol* 2007 ; 17 : 123-30. PMID : 17437167
21. Fujisawa T, et al. Prognostic factors for myositis-associated interstitial lung disease. *PLoS One* 2014 ; 9 : e98824. PMID : 24905449
22. Miller FW, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. *N Engl J Med* 1992 ; 326 : 1380-4. PMID : 1472183
23. Yagishita M, et al. Clinically Amyopathic Dermatomyositis with Interstitial Pneumonia That Was Successfully Treated with Plasma Exchange. *Intern Med* 2018 ; 57 : 1935-8. PMID : 29491297
24. Endo Y, et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis : A case report. *Medicine (Baltimore)* 2018 ; 97 : e0436. PMID : 29642214
25. Teruya A, et al. Successful polymyxin B hemoperfusion treatment associated with

- serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. *Chest* 2013 ; 144 : 1934-6. PMID : 24297126
26. Dalakas MC, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. *N Engl J Med* 1993 ; 329 : 1993-2000. PMID : 8247075
27. Cherin P, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis : an open study with thirty-five adult patients. *Arthritis Rheum* 2002 ; 46 : 467-74. PMID : 11840450
28. Marie I, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis : a series of 73 patients. *Arthritis Care Res (Hoboken)* 2010 ; 62 : 1748-55. PMID : 20722047
29. Suzuki Y, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. *Lung* 2009 ; 187 : 201-6. PMID : 19387736

●リンクページ

- 特発性炎症性筋疾患の分類基準 (web 計算機)
<<http://www.imm.ki.se/biostatistics/calculators/iim/jp.html>>

第6章 血管炎

●参考文献

1. Stone JH. Classification and Epidemiology of Systemic Vasculitis. In : Firestein GS, et al. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Philadelphia : Elsevier, 2016 : 1512-9.
2. Radić M, et al. Drug-induced vasculitis : a clinical and pathological review. *Neth J Med* 2012 ; 70 : 12-7. PMID : 22271809
3. Kobayashi S, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan : the first government-supported nationwide survey. *Arthritis Rheum* 2003 ; 49 : 594-8. PMID : 12910568
4. Watanabe Y, et al. Current Clinical Features of New Patients With Takayasu Arteritis Observed From Cross-Country Research in Japan : Age and Sex Specificity. *Circulation* 2015 ; 132 : 1701-9. PMID : 26354799
5. Pagnoux C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa : a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. *Arthritis Rheum* 2010 ; 62 : 616-26. PMID : 20112401
6. 横野博史ほか. ANCA 関連血管炎の診断と治療の現況. *日内会誌* 2011 ; 100 : 668-72.
7. Hellmark T, et al. Diagnosis and classification of Goodpasture's disease (anti-GBM). *J Autoimmun* 2014 ; 48-9 : 108-12. PMID : 24456936
8. Audemard-Verger A, et al. Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults : Data From 260 Patients Included in a French Multi-center Retrospective Survey. *Arthritis Rheumatol* 2017 ; 69 : 1862-70. PMID : 28605168

- Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum* 1990 ; 33 : 1129-34. PMID : 1975175
- Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum* 1990 ; 33 : 1122-8. PMID : 2202311
- Seeliger B, et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? *Rheumatology (Oxford)* 2017 ; 56 : 1154-61. PMID : 28379475
- Watts R, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis* 2007 ; 66 : 222-7. PMID : 16901958
- Masi AT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). *Arthritis Rheum* 1990 ; 33 : 1094-100. PMID : 2202307
- Leavitt RY, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum* 1990 ; 33 : 1101-7. PMID : 2202308
- Lightfoot RW, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. *Arthritis Rheum* 1990 ; 33 : 1088-93. PMID : 1975174
- Muratore F, et al. Large-vessel giant cell arteritis : a cohort study. *Rheumatology (Oxford)* 2015 ; 54 : 463-70. PMID : 25193809
- Watts RA, et al. Introduction, epidemiology and classification of vasculitis. *Best Pract Res Clin Rheumatol* 2018 ; 32 : 3-20. PMID : 30526896
- Hellmich B, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis* 2020 ; 79 : 19-30. PMID : 31270110

● 推奨文献

- 難病指定センター. 難治性血管炎に関する調査研究. <<http://www.nanbyou.or.jp/entry/1527>>
- 厚生労働省 難治性疾患政策研究事業 難治性血管炎に関する調査研究班. 2015-2016 年度活動 血管炎症候群の診療ガイドライン (2017 年改訂版) <http://www.j-circ.or.jp/guideline/pdf/JCS2017_isobe_h.pdf> **ガイドライン**
- Jennette JC, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013 ; 65 : 1-11. PMID : 23045170
- Yates M, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Ann Rheum Dis* 2016 ; 75 : 1583-94. PMID : 27338776

第7章 成人Still病 (AOSD)

● 参考文献

- Asanuma YF, et al. Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. *Mod Rheumatol* 2015 ; 25 : 393-400. PMID : 25382730
- Cush JJ, et al. Adult - onset still's disease. *Arthritis Rheumatol* 1987 ; 30 : 186-94.
- Lee JY, et al. Evanescent and persistent pruritic eruptions of adult-onset still disease : a clinical and pathologic study of 36 patients. *Semin Arthritis Rheum* 2012 ; 42 : 317-26. PMID : 22717204

4. Lee JY, et al. Histopathology of persistent papules and plaques in adult-onset Still's disease. *J Am Acad Dermatol* 2005 ; 52 : 1003-8. PMID : 15928619
5. 厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究班. 成人スチル病診療ガイドライン 2017年版. 東京 : 診断と治療社, 2017. <https://minds.jqhc.or.jp/docs/gl_pdf/G0001020/4/Adult_Stills_Disease.pdf> **ガイドライン**
6. Yamaguchi M, et al. Preliminary criteria for classification of adult Still's disease. *J Rheumatol* 1992 ; 19 : 424-30. PMID : 1578458
7. Masson C, et al. Comparative study of 6 types of criteria in adult Still's disease. *J Rheumatol* 1996 ; 23 : 495-7. PMID : 8832990
8. Henter JI, et al. HLH-2004 : Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2007 ; 48 : 124-31. PMID : 16937360 **ガイドライン**

第8章 IgG4関連疾患

◎参考文献

1. Stone JH, et al. IgG4-related disease. *N Engl J Med* 2012 ; 366 : 539-51. PMID : 22316447
2. Umehara H, et al. A novel clinical entity, IgG4-related disease (IgG4RD) : general concept and details. *Mod Rheumatol* 2012 ; 22 : 1-14. PMID : 21881964
3. Kamisawa T, et al. IgG4-related disease. *Lancet* 2015 ; 385 : 1460-71. PMID : 25481618
4. Kanno A, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan. *Pancreas* 2012 ; 41 : 835-9. PMID : 22466167
5. Wallace ZS, et al. IgG4-Related Disease : Clinical and Laboratory Features in One Hundred Twenty-Five Patients. *Arthritis Rheumatol* 2015 ; 67 : 2466-75. PMID : 25988916
6. Wallace ZS, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. *Ann Rheum Dis* 2020 ; 79 : 77-87. PMID : 31796497
7. Saeki T, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. *Kidney Int* 2010 ; 78 : 1016-23. PMID : 20720530
8. Alexander MP, et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. *Kidney Int* 2013 ; 83 : 455-62. PMID : 23254897
9. Pieringer H, et al. IgG4-related disease : an orphan disease with many faces. *Orphanet J Rare Dis* 2014 ; 9 : 110. PMID : 25026959
10. Stone JH, et al. IgG4-Related Disease. In : Kelley and Firestein's Textbook of Rheumatology, 10th ed. Philadelphia : Elsevier, 2016 : 2026-36.
11. Umehara H, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. *Mod Rheumatol* 2012 ; 22 : 21-30. PMID : 22218969
12. Hao M, et al. Diagnostic Value of Serum IgG4 for IgG4-Related Disease : A PRISMA-compliant Systematic Review and Meta-analysis. *Medicine (Baltimore)* 2016 ; 95 : e3785. PMID : 27227950
13. Culver EL, et al. Elevated Serum IgG4 Levels in Diagnosis, Treatment Response,

- Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort. *Am J Gastroenterol* 2016 ; 111 : 733-43. PMID : 27091321
14. Tang J, et al. Biomarkers in IgG4-related disease : A systematic review. *Semin Arthritis Rheum* 2020 ; 50 : 354-9. PMID : 31280934
 15. Wallace ZS, et al. Predictors of disease relapse in IgG4-related disease following rituximab. *Rheumatology (Oxford)* 2016 ; 55 : 1000-8. PMID : 26888853
 16. Okazaki K, et al. Clinical diagnostic criteria of autoimmune pancreatitis : revised proposal. *J Gastroenterol* 2006 ; 41 : 626-31. PMID : 16932998
 17. Masaki Y, et al. IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis : diagnostic insights. *J Rheumatol* 2010 ; 37 : 1380-5. PMID : 20436071
 18. Kawano M, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. *Clin Exp Nephrol* 2011 ; 15 : 615-26. PMID : 21898030
 19. Ebbo M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease : Data from a French nationwide study of thirty-three patients. *PLoS One* 2017 ; 12 : e0183844. PMID : 28915275
 20. Asano J, et al. Association Between Immunoglobulin G4-related Disease and Malignancy within 12 Years after Diagnosis : An Analysis after Longterm Followup. *J Rheumatol* 2015 ; 42 : 2135-42. PMID : 26472416